Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 23,640 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 23,640 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $1.07, for a total transaction of $25,294.80. Following the completion of the sale, the director owned 2,866,488 shares in the company, valued at $3,067,142.16. The trade was a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $11,380.62.
• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.05, for a total value of $15,275.40.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total value of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total value of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.06, for a total value of $39,330.24.
• On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.01, for a total value of $45,015.70.
• On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $33,700.59.
• On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total transaction of $16,070.96.
• On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $51,813.52.
• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total transaction of $31,951.62.

Werewolf Therapeutics Stock Down 43.8%

Shares of Werewolf Therapeutics stock traded down $0.47 on Thursday, hitting $0.60. 3,193,548 shares of the company traded hands, compared to its average volume of 508,030. The company has a 50-day moving average price of $1.22 and a 200 day moving average price of $1.32. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 12-month low of $0.56 and a 12-month high of $2.38. The company has a market cap of $29.17 million, a PE ratio of -0.36 and a beta of 0.74.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. Sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Quadrature Capital Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter valued at $28,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics during the 2nd quarter worth about $48,000. Nuveen LLC bought a new position in shares of Werewolf Therapeutics during the 1st quarter worth about $71,000. AQR Capital Management LLC acquired a new position in shares of Werewolf Therapeutics during the first quarter valued at about $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics in the second quarter valued at about $92,000. Institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HOWL. Bank of America decreased their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, JMP Securities lowered their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.